[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"henoch-schnlein-purpura-nephritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:henoch-schnlein-purpura-nephritis":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100656203","to-assess-the-efficacy-and-safety-of-utilizing-galactose-deficient-iga1-biomarker-changes-to-guide-pathogenic-iga-targeted-therapeutic-strategies-100656203",false,"NCT07822100","To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies","Development and Validation of a Gd-IgA1 Guided Precision Therapy System for Targeted Therapeutic Strategies of IgA Nephropathy： An Open-label, Random Controlled Trial","Inclusion Criteria:\n\n* Male or female, between 18 and 75 years age;\n* Biopsy confirmed diagnosis of primary IgA nephropathy or IgA Vasculitis-Associated Nephritis;\n* Persistent proteinuria, defined as: two separate measurements (with an interval of ≥ 4 weeks) of 24-hour urinary protein excretion (24hUTP) ≥ 0.5 g\u002Fday, or urine protein-to-creatinine ratio (UPCR) ≥ 0.44 g\u002Fg;\n* Estimated glomerular filtration rate (eGFR) (CKD-EPI) ≥ 30 ml\u002Fmin per 1.73m\\^2;\n* Have received the angiotensin converting enzyme Inhibitors(ACEI) \u002F angiotensin receptor blocker(ARB) standard treatment for 4 weeks prior to randomization;\n* Intending to receive or having received Nefecon or telitacicept treatment for ≤ 2 weeks at the time of screening.\n\nExclusion Criteria:\n\n* Secondary IgA nephropathy (excluding IgA vasculitis) caused by ankylosing spondylitis, systemic lupus erythematosus, viral hepatitis, liver cirrhosis, etc.;\n* With a known history or clinical evidence of concurrent renal diseases other than IgA nephropathy;\n* Treating with systemic corticosteroids or immunosuppressants including cyclophosphamide, azathioprine, mycophenolate mofetil, tacrolimus, cyclosporine, rituximab, etc. within 3 months prior to randomizing;\n* Have initiated or had a dose adjustment of leflunomide, tripterygium wilfordii or hydroxychloroquine within 3 months prior to randomizing;\n* Active tuberculosis or latent carrier without treatment;\n* Herpes zoster infected patients or patients with positive HIV antibody, positive HCV antibody or HBV infection (According to the HBV screening test, a) the HBsAg-positive; b) HBsAg-negative and HBcAb-positive, the HBV-DNA should be tested to determine the situation: the HBV-DNA positive subjects should be excluded, while the HBV-DNA negative subjects can participated in.)\n* Suffering from following gastrointestinal diseases: gastric ulcer bleeding within the past 6 months, active inflammatory bowel disease, a history of major gastrointestinal surgery (e.g., gastrectomy, gastroenterostomy, or bowel resection), or pancreatic injury\u002Fpancreatitis within the past 6 months;\n* A confirmed history of osteoporosis or osteonecrosis of the femoral head;\n* Type 1 or type 2 diabetes with poor glycemic control (HbA1c \\> 8%);\n* Body mass index (BMI) \\\u003C 18.5 kg\u002Fm².;\n* Systolic blood pressure (SBP) \\> 180 mmHg or diastolic blood pressure (DBP) \\> 110 mmHg;\n* Decreased lymphocyte count (absolute value \\\u003C 1.1 × 10⁹\u002FL) or decreased immunoglobulin G (IgG \\\u003C 6 g\u002FL).\n* Hepatic dysfunction, meeting any of the following: a) Child-Pugh Class C liver dysfunction; b) ALT or AST \\> 2 × upper limit of normal (ULN), or total bilirubin \\> 2 × ULN at screening; c) history of hepatic encephalopathy, esophageal varices, or portosystemic shunt surgery;\n* Evidence of urinary tract obstruction or dysuria.\n* A history of solid organ transplantation, hematopoietic stem cell\u002Fcell\u002Fbone marrow transplantation, or kidney transplantation.\n* Pregnancy, lactation, female participants with childbearing plans during the trial or within 6 months of its completion, and male participants planning to conceive or donate sperm during the trial or within 3 months of its completion;\n* With a history of malignant tumors within the past 5 years (excluding cutaneous squamous cell carcinoma or basal cell carcinoma);\n* Allergy to human-derived biologics;\n* Nephrotoxic drugs is unavoidable during the study period;\n* Not suitable for the study judged by investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},374,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this open-label, randomized study is to evaluate the efficacy and safety of the personalized treatment model in which Gd-IgA1 is dynamically monitored to guide medication adjustment in progressive IgAN patients treated with Nefecon or telitacicept.\n\nResearchers will compare two groups of participants: those who have Gd-IgA1 checked regularly during treatment, and those who do not. This is to find out if regular Gd-IgA1 checks can help doctors adjust medication better and get better treatment results.",[27,28],"IgA Nephropathy (IgAN)","Henoch Schönlein Purpura Nephritis",[30,31,32],"IgA Nephropathy","IgA Vasculitis Nephritis","Gd-IgA1","RECRUITING","2026-09-10",{"date":36,"type":37},"2026-09-16","ACTUAL",{"date":39,"type":37},"2026-08-24",{"date":41,"type":21},"2028-02",{"name":43,"class":44},"Hong Zhang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100617174","phase-4-finerenone-therapy-for-pediatric-hspn-with-mild-proteinuria-100617174","NCT07315191","Finerenone Therapy for Pediatric HSPN With Mild Proteinuria","The Randomized Controlled Trial of Finerenone Therapy for Pediatric Hennoch Scholein Nephritis With Mild Proteinuria","FICHSPN","Inclusion Criteria:\n\n1. Children of HSPN meet the following conditions① Age \\> 3 years old and \\\u003C 18 years old;\n2. 24-hour urine protein quantification \\>= 8mg\u002Fh\u002FM2 body surface area (or \\>= 300mg\u002Fd), and \\\u003C 20mg\u002Fh\u002FM2 body surface area (\\\u003C 1000mg\u002Fd);\n\n3: 3. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Abnormal renal function: eGFR \\\u003C 90 ml\u002Fmin\u002F1.73m\\^2 body surface area;\n2. Renal pathological grade \\>= IV;\n3. Application of glucocorticoids and\u002For immunosuppressants within 2 weeks;\n4. Recent applications involving high-dose glucocorticoids administered for a duration exceeding two weeks.;\n5. Liver transaminase \\> 2 times the upper limit of normal;\n6. Severe cardiac insufficiency;\n7. Simultaneous use of CYPA4 inhibitors;-","3 Years",{"count":56,"type":21},116,[58],"PHASE4","Henoch-Schönlein purpura nephritis (HSPN) is the most common secondary glomerular disease in children. About 40% of HSPN cases are accompanied by mild proteinuria, and some of them progress to end-stage renal disease. Currently, the treatment for children with mild proteinuria HSPN mainly involves ACEI\u002FARB, but long-term use of these drugs can lead to an increase in aldosterone levels, affecting therapeutic efficacy. Finerenone can improve vascular endothelial cell dysfunction and renal tissue inflammation and fibrosis, and reduce urinary protein in patients with glomerular diseases. This study intends to conduct an exploratory randomized controlled clinical trial of finerenone in children with HSPN accompanied by a small amount of proteinuria to evaluate the efficacy and safety of finerenone treatment.",[28],"2026-01-05",{"date":63,"type":37},"2026-01-07",{"date":65,"type":37},"2025-06-13",{"date":67,"type":21},"2028-04-30",{"name":69,"class":44},"Capital Institute of Pediatrics, China","Henoch-Schönlein Purpura Nephritis"]